Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 5Neoplasm Metastasis 3Endometrial Neoplasms 3Ovarian Neoplasms 2Multiple Myeloma 2Mouth Neoplasms 2Lymphoma 2Laryngeal Neoplasms 2Hypopharyngeal Neoplasms 2Carcinoma 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Neoplasms 1Melanoma 1Lung Neoplasms 1Hematologic Neoplasms 1Glioma 1Fallopian Tube Neoplasms 1FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma 1Esophageal Neoplasms 1

Interventions

pembrolizumab 44Carboplatin 35Paclitaxel 27Specimen Handling 18Cyclophosphamide 16Capecitabine 16Magnetic Resonance Spectroscopy 14sacituzumab govitecan 13Gemcitabine 13Taxes 12Biopsy 12130-nm albumin-bound paclitaxel 11Albumin-Bound Paclitaxel 9Doxorubicin 8olaparib 7Nivolumab 7fludarabine 6Cisplatin 6eribulin 5atezolizumab 5Radiotherapy 5Docetaxel 5durvalumab 4Fulvestrant 4Epirubicin 4Bevacizumab 4veliparib 3famitinib 3abemaciclib 3Vinorelbine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × ipatasertib × 90 days × Clear all
NCT05498896 2026-05-08

BARBICAN

Queen Mary University of London

Phase 2 Active not recruiting
146 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡